Overview
SUPN market data
Price History
SUPN price chart · 1M
- O
- 45.20
- H
- 45.38
- L
- 44.56
- C
- 44.92
- Vol
- 48,652.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $45.20
- Previous Close
- $45.40
- Day High
- $45.38
- Day Low
- $44.56
- 52 Week High
- $56.00
- 52 Week Low
- $42.50
- 7 Day Return
- -7.48%
- 30 Day Return
- -4.38%
- 90 Day Return
- -4.10%
- 1 Year Return
- -16.61%
- Daily Notional Volume
- $2.2M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.68 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.56 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -13.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.45 – $59.68 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7B · P/B 2.68 · P/S 3.30.
Company News
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 17, 2026, 9:20 AM
Top 3 Health Care Stocks You'll Regret Missing This QuarterBenzinga · Aug 4, 2026, 10:04 AM
Why Supernus Pharmaceuticals Stock Topped the Market TodayThe Motley Fool · Aug 3, 2026, 11:15 PM
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their ShareholdersGlobenewswire Inc · Aug 3, 2026, 9:31 PM
8-K filing — SUPERNUS PHARMACEUTICALS, INC. (SUPN)SEC EDGAR · Aug 3, 2026, 9:00 PM
Supernus Pharma shares are trading higher after the company reported better-than-expected Q2 financial results. The company also announced a merger with Indivior Pharma to create diversified, CNS biopharmaceutical company.Benzinga · Aug 3, 2026, 5:56 PM
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in RevenueBenzinga · Aug 3, 2026, 2:44 PM
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 EstimateBenzinga · Aug 3, 2026, 1:27 PM
Supernus Pharmaceuticals Q2 EPS $(1.01) Misses $0.07 Estimate, Sales $219.058M Beat $204.962M EstimateBenzinga · Aug 3, 2026, 10:41 AM
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost SynergiesBenzinga · Aug 3, 2026, 10:35 AM